English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Azithromycin has been widely used for  Mycoplasma genitalium  treatment internationally. However, the eradication efficacy has substantially declined recent decade .  In Russia, josamycin (another macrolide) is the recommended first-line treatment for  M. genitalium  infections, however, no data regarding treatment efficacy with josamycin and resistance in  M. genitalium  infections have been internationally published. We examined the  M. genitalium  prevalence in males attending an STI clinic in Moscow, Russia from December 2006 to January 2008, investigated treatment efficacy with josamycin in male urethritis, and monitored the  M. genitalium  DNA eradication dynamics and selection of macrolide resistance in  M. genitalium  during this treatment.    Methods  Microscopy and real-time PCRs were used to diagnose urethritis and non-viral STIs, respectively, in males (n = 320).  M. genitalium  positive patients were treated with recommended josamycin regimen and treatment efficacy was monitored using quantitative real-time PCR. Macrolide resistance mutations were identified using sequencing of the 23S rRNA gene.    Results  Forty-seven (14.7%) males were positive for  M. genitalium  only and most (85.1%) of these had symptoms and signs of urethritis. Forty-six (97.9%) males agreed to participate in the treatment efficacy monitoring. All the pre-treatment  M. genitalium  specimens had wild-type 23S rRNA. The elimination of  M. genitalium  DNA was substantially faster in patients with lower pre-treatment  M. genitalium  load, and the total eradication rate was 43/46 (93.5%). Of the six patients with high pre-treatment  M. genitalium  load, three (50%) remained positive post-treatment and these positive specimens contained macrolide resistance mutations in the 23S rRNA gene, i.e., A2059G (n = 2) and A2062G (n = 1).    Conclusions   M. genitalium  was a frequent cause of male urethritis in Moscow, Russia. The pre-treatment  M. genitalium  load might be an effective predictor of eradication efficacy with macrolides (and possibly additional antimicrobials) and selection of macrolide resistance. Additional  in vivo  and  in vitro  data are crucial to support the recommendation of using josamycin as first-line treatment for  M. genitalium  infections in Russia. It would be valuable to develop international  M. genitalium  management guidelines, and quantitative diagnostic PCRs determining also  M. genitalium  load and resistance mutations (for macrolides and ideally also moxifloxacin) should ideally be recommended.

bmc infectious diseases

Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin